I understand where you are coming from but think it depends.

For example, imagine this specific scenario.

3 point MACE reduction in all is 20% with a p value of 0.06.

3 point MACE reduction in Crestor group is 35% with a p value of 0.02.

Apabetalone group shows increased GFR by 5% vs -5% in placebo group (p=0.02).

Apabetalone shows significant affect on cognitive decline.

So, the topline would be a miss.

However, RVX could file for a Rosuvastatin/Apabetalone combo drug that has beneficial effects on 3 point MACE, GFR and cognitive status in the study group.

In this scenario (completely made up but possible), I don’t see the stock retreating to 15 cents. In fact, if the message is properly curated (Rothschild), the stock could fly.

bfw